

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamcgl632

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <a href="http://download.cas.org/express/v8.0-Discover/">http://download.cas.org/express/v8.0-Discover/</a>
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:28:35 ON 25 APR 2006

=> f biosis medline embase scisearch

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file biosis medline embase scisearch

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'BIOSIS' ENTERED AT 10:29:37 ON 25 APR 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 10:29:37 ON 25 APR 2006

FILE 'EMBASE' ENTERED AT 10:29:37 ON 25 APR 2006

Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 10:29:37 ON 25 APR 2006

Copyright (c) 2006 The Thomson Corporation

=> s melusin

L1 75 MELUSIN

=> s L1 and trasngenic

L2 0 L1 AND TRASNGENIC

=> s L1 and transgenic

L3 4 L1 AND TRANSGENIC

=> d L3 all

L3 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

AN 2005:334635 BIOSIS

DN PREV200510121520

TI Cardiac overexpression of **melusin** protects from dilated cardiomyopathy due to long-standing pressure overload.

AU De Acetis, Marika; Notte, Antonella; Accornero, Federica; Selvetella, Giulio; Brancaccio, Mara; Vecchione, Carmine; Sbroggio, Mauro; Collino, Federica; Pacchioni, Beniamina; Lanfranchi, Gerolamo; Aretini, Alessandra; Ferretti, Roberta; Maffei, Angelo; Altruda, Fiorella; Silengo, Lorenzo; Tarone, Guido [Reprint Author]; Lembo, Giuseppe

CS Univ Turin, Dept Genet Biol and Biochem, Via Santena, 5Bis, I-10126 Turin, Italy

guido.tarone@unito.it; lembo@neuromed.it

SO Circulation Research, (MAY 27 2005) Vol. 96, No. 10, pp. 1087-1094.

CODEN: CIRUAL. ISSN: 0009-7330.

DT Article

LA English

ED Entered STN: 31 Aug 2005

Last Updated on STN: 31 Aug 2005

AB We have previously shown that genetic ablation of **melusin**, a muscle specific beta 1 integrin interacting protein, accelerates left ventricle (LV) dilation and heart failure in response to pressure

overload. Here we show that **melusin** expression was increased during compensated cardiac hypertrophy in mice subjected to 1 week pressure overload, but returned to basal levels in LV that have undergone dilation after 12 weeks of pressure overload. To better understand the role of **melusin** in cardiac remodeling, we overexpressed **melusin** in heart of **transgenic** mice. Echocardiography analysis indicated that **melusin** over-expression induced a mild cardiac hypertrophy in basal conditions (30% increase in interventricular septum thickness) with no obvious structural and functional alterations. After prolonged pressure overload (12 weeks), **melusin** overexpressing hearts underwent further hypertrophy retaining concentric LV remodeling and full contractile function, whereas wild-type LV showed pronounced chamber dilation with an impaired contractility. Analysis of signaling pathways indicated that **melusin** overexpression induced increased basal phosphorylation of GSK3 beta and ERK1/2. Moreover, AKT, GSK3 beta and ERK1/2 were hyper-phosphorylated on pressure overload in **melusin** overexpressing compared with wild-type mice. In addition, after 12 weeks of pressure overload LV of **melusin** overexpressing mice showed a very low level of cardiomyocyte apoptosis and stromal tissue deposition, as well as increased capillary density compared with wild-type. These results demonstrate that **melusin** overexpression allows prolonged concentric compensatory hypertrophy and protects against the transition toward cardiac dilation and failure in response to long-standing pressure overload.

CC Cytology - General 02502  
 Cytology - Animal 02506  
 Biochemistry studies - General 10060  
 Pathology - General 12502  
 Cardiovascular system - Physiology and biochemistry 14504  
 Cardiovascular system - Heart pathology 14506  
 Muscle - Physiology and biochemistry 17504

IT Major Concepts  
 Biochemistry and Molecular Biophysics; Cell Biology; Cardiovascular System (Transport and Circulation)

IT Parts, Structures, & Systems of Organisms  
 cardiomyocyte: muscular system, circulatory system; muscle: muscular system; left ventricle: circulatory system; stromal tissue

IT Diseases  
 heart failure: heart disease  
 Heart Failure, Congestive (MeSH)

IT Diseases  
 dilated cardiomyopathy: heart disease, pathology  
 Cardiomyopathy, Congestive (MeSH)

IT Chemicals & Biochemicals  
 ERK1/2; AKT; GSK3-beta; **melusin**: expression

IT Methods & Equipment  
 echocardiography: laboratory techniques, diagnostic techniques, clinical techniques, imaging and microscopy techniques; genetic ablation: laboratory techniques, genetic techniques

IT Miscellaneous Descriptors  
 pressure overload; capillary density; cardiac remodeling; interventricular septum thickness

ORGN Classifier  
 Muridae 86375  
 Super Taxa  
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia  
 Organism Name  
 mouse (common): **transgenic**  
 Taxa Notes  
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals, Rodents, Vertebrates

=> d L3 1-4 all

L3 ANSWER 1 OF 4 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN  
 AN 2005:334635 BIOSIS  
 DN PREV200510121520  
 TI Cardiac overexpression of **melusin** protects from dilated  
 cardiomyopathy due to long-standing pressure overload.  
 AU De Acetis, Marika; Notte, Antonella; Accornero, Federica; Selvetella,  
 Giulio; Brancaccio, Mara; Vecchione, Carmine; Sbroggio, Mauro; Collino,  
 Federica; Pacchioni, Beniamina; Lanfranchi, Gerolamo; Aretini, Alessandra;  
 Ferretti, Roberta; Maffei, Angelo; Altruda, Fiorella; Silengo, Lorenzo;  
 Tarone, Guido [Reprint Author]; Lembo, Giuseppe  
 CS Univ Turin, Dept Genet Biol and Biochem, Via Santena,5Bis, I-10126 Turin,  
 Italy  
 guido.tarone@unito.it; lembo@neuromed.it  
 SO Circulation Research, (MAY 27 2005) Vol. 96, No. 10, pp. 1087-1094.  
 CODEN: CIRUAL. ISSN: 0009-7330.  
 DT Article  
 LA English  
 ED Entered STN: 31 Aug 2005  
 Last Updated on STN: 31 Aug 2005  
 AB We have previously shown that genetic ablation of **melusin**, a  
 muscle specific beta 1 integrin interacting protein, accelerates left  
 ventricle ( LV) dilation and heart failure in response to pressure  
 overload. Here we show that **melusin** expression was increased  
 during compensated cardiac hypertrophy in mice subjected to 1 week  
 pressure overload, but returned to basal levels in LV that have undergone  
 dilation after 12 weeks of pressure overload. To better understand the  
 role of **melusin** in cardiac remodeling, we overexpressed  
**melusin** in heart of **transgenic** mice. Echocardiography  
 analysis indicated that **melusin** over-expression induced a mild  
 cardiac hypertrophy in basal conditions (30% increase in interventricular  
 septum thickness) with no obvious structural and functional alterations.  
 After prolonged pressure overload (12 weeks), **melusin**  
 overexpressing hearts underwent further hypertrophy retaining concentric  
 LV remodeling and full contractile function, whereas wild-type LV showed  
 pronounced chamber dilation with an impaired contractility. Analysis of  
 signaling pathways indicated that **melusin** overexpression induced  
 increased basal phosphorylation of GSK3 beta and ERK1/2. Moreover, AKT,  
 GSK3 beta and ERK1/2 were hyper-phosphorylated on pressure overload in  
**melusin** overexpressing compared with wild-type mice. In addition,  
 after 12 weeks of pressure overload LV of **melusin** overexpressing  
 mice showed a very low level of cardiomyocyte apoptosis and stromal tissue  
 deposition, as well as increased capillary density compared with  
 wild-type. These results demonstrate that **melusin**  
 overexpression allows prolonged concentric compensatory hypertrophy and  
 protects against the transition toward cardiac dilation and failure in  
 response to long-standing pressure overload.  
 CC Cytology - General 02502  
 Cytology - Animal 02506  
 Biochemistry studies - General 10060  
 Pathology - General 12502  
 Cardiovascular system - Physiology and biochemistry 14504  
 Cardiovascular system - Heart pathology 14506  
 Muscle - Physiology and biochemistry 17504  
 IT Major Concepts  
 Biochemistry and Molecular Biophysics; Cell Biology; Cardiovascular  
 System (Transport and Circulation)  
 IT Parts, Structures, & Systems of Organisms  
 cardiomyocyte: muscular system, circulatory system; muscle: muscular  
 system; left ventricle: circulatory system; stromal tissue  
 IT Diseases  
 heart failure: heart disease  
 Heart Failure, Congestive (MeSH)  
 IT Diseases

dilated cardiomyopathy: heart disease, pathology  
 Cardiomyopathy, Congestive (MeSH)

IT Chemicals & Biochemicals  
 ERK1/2; AKT; GSK3-beta; melusin: expression

IT Methods & Equipment  
 echocardiography: laboratory techniques, diagnostic techniques,  
 clinical techniques, imaging and microscopy techniques; genetic  
 ablation: laboratory techniques, genetic techniques

IT Miscellaneous Descriptors  
 pressure overload; capillary density; cardiac remodeling;  
 interventricular septum thickness

ORGN Classifier  
 Muridae 86375  
 Super Taxa  
 Rodentia; Mammalia; Vertebrata; Chordata; Animalia  
 Organism Name  
 mouse (common): **transgenic**  
 Taxa Notes  
 Animals, Chordates, Mammals, Nonhuman Vertebrates, Nonhuman Mammals,  
 Rodents, Vertebrates

L3 ANSWER 2 OF 4 MEDLINE on STN  
 AN 2005276325 MEDLINE  
 DN PubMed ID: 15860758  
 TI Cardiac overexpression of **melusin** protects from dilated  
 cardiomyopathy due to long-standing pressure overload.

AU De Acetis Marika; Notte Antonella; Accornero Federica; Selvetella Giulio;  
 Brancaccio Mara; Vecchione Carmine; Sbroggio Mauro; Collino Federica;  
 Pacchioni Beniamina; Lanfranchi Gerolamo; Aretini Alessandra; Ferretti  
 Roberta; Maffei Angelo; Altruda Fiorella; Silengo Lorenzo; Tarone Guido;  
 Lembo Giuseppe

CS Department of Genetics, Biology, Turin University, Turin, Italy.  
 SO Circulation research, (2005 May 27) Vol. 96, No. 10, pp. 1087-94.  
 Electronic Publication: 2005-04-28.  
 Journal code: 0047103. E-ISSN: 1524-4571.

CM Erratum in: Circ Res. 2005 Jul 8;97(1):e5  
 CY United States  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200510  
 ED Entered STN: 28 May 2005  
 Last Updated on STN: 12 Oct 2005  
 Entered Medline: 11 Oct 2005

AB We have previously shown that genetic ablation of **melusin**, a  
 muscle specific beta 1 integrin interacting protein, accelerates left  
 ventricle (LV) dilation and heart failure in response to pressure  
 overload. Here we show that **melusin** expression was increased  
 during compensated cardiac hypertrophy in mice subjected to 1 week  
 pressure overload, but returned to basal levels in LV that have undergone  
 dilation after 12 weeks of pressure overload. To better understand the  
 role of **melusin** in cardiac remodeling, we overexpressed  
**melusin** in heart of **transgenic** mice. Echocardiography  
 analysis indicated that **melusin** over-expression induced a mild  
 cardiac hypertrophy in basal conditions (30% increase in interventricular  
 septum thickness) with no obvious structural and functional alterations.  
 After prolonged pressure overload (12 weeks), **melusin**  
 overexpressing hearts underwent further hypertrophy retaining concentric  
 LV remodeling and full contractile function, whereas wild-type LV showed  
 pronounced chamber dilation with an impaired contractility. Analysis of  
 signaling pathways indicated that **melusin** overexpression induced  
 increased basal phosphorylation of GSK3beta and ERK1/2. Moreover, AKT,  
 GSK3beta and ERK1/2 were hyper-phosphorylated on pressure overload in  
**melusin** overexpressing compared with wild-type mice. In addition,

after 12 weeks of pressure overload LV of **melusin** overexpressing mice showed a very low level of cardiomyocyte apoptosis and stromal tissue deposition, as well as increased capillary density compared with wild-type. These results demonstrate that **melusin** overexpression allows prolonged concentric compensatory hypertrophy and protects against the transition toward cardiac dilation and failure in response to long-standing pressure overload.

CT

Animals  
Apoptosis  
Blood Pressure  
Cardiomyopathy, Dilated: ET, etiology  
\*Cardiomyopathy, Dilated: PC, prevention & control  
Cytoskeletal Proteins: GE, genetics  
\*Cytoskeletal Proteins: PH, physiology  
Fibrosis  
Glycogen Synthase Kinase 3: ME, metabolism  
Humans  
Hypertrophy, Left Ventricular: ET, etiology  
Mice

#### Mice, Transgenic

Mitogen-Activated Protein Kinase 1: PH, physiology  
Mitogen-Activated Protein Kinase 3: PH, physiology  
Muscle Proteins: GE, genetics  
\*Muscle Proteins: PH, physiology  
\*Myocardium: ME, metabolism  
Myocardium: PA, pathology  
Myocytes, Cardiac: PA, pathology  
Phosphorylation  
Protein-Serine-Threonine Kinases: ME, metabolism  
Proto-Oncogene Proteins: ME, metabolism  
Proto-Oncogene Proteins c-akt  
Rats  
Rats, Sprague-Dawley  
Research Support, Non-U.S. Gov't  
Ventricular Remodeling

CN

0 (Cytoskeletal Proteins); 0 (Itgblbp2 protein, mouse); 0 (Muscle Proteins); 0 (Proto-Oncogene Proteins); EC 2.7.1.37 (AKT1 protein, human); EC 2.7.1.37 (Akt1 protein, rat); EC 2.7.1.37 (Glycogen Synthase Kinase 3); EC 2.7.1.37 (Mitogen-Activated Protein Kinase 1); EC 2.7.1.37 (Mitogen-Activated Protein Kinase 3); EC 2.7.1.37 (Protein-Serine-Threonine Kinases); EC 2.7.1.37 (Proto-Oncogene Proteins c-akt); EC 2.7.1.37 (glycogen synthase kinase 3 beta)

L3

ANSWER 3 OF 4 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN

AN

2005254947 EMBASE

TI

Cardiac overexpression of **melusin** protects from dilated cardiomyopathy due to long-standing pressure overload.

AU

De Acetis M.; Notte A.; Accornero F.; Selvetella G.; Brancaccio M.; Vecchione C.; Sbroglio M.; Collino F.; Pacchioni B.; Lanfranchi G.; Aretini A.; Ferretti R.; Maffei A.; Altruda F.; Silengo L.; Tarone G.; Lembo G.

CS

G. Tarone, Dept. of Genetics, Biology, and Biochemistry, Turin University, Via Santena, 5bis, 10126 Turin, Italy. [guido.tarone@unito.it](mailto:guido.tarone@unito.it)

SO

Circulation Research, (27 May 2005) Vol. 96, No. 10, pp. 1087-1094. . Refs: 27

ISSN: 0009-7330 CODEN: CIRUAL

CY

United States

DT

Journal; Article

FS

005 General Pathology and Pathological Anatomy

014 Radiology

018 Cardiovascular Diseases and Cardiovascular Surgery

029 Clinical Biochemistry

LA

English

SL English

ED Entered STN: 30 Jun 2005

Last Updated on STN: 30 Jun 2005

AB We have previously shown that genetic ablation of **melusin**, a muscle specific  $\beta$  1 integrin interacting protein, accelerates left ventricle (LV) dilation and heart failure in response to pressure overload. Here we show that **melusin** expression was increased during compensated cardiac hypertrophy in mice subjected to 1 week pressure overload, but returned to basal levels in LV that have undergone dilation after 12 weeks of pressure overload. To better understand the role of **melusin** in cardiac remodeling, we overexpressed **melusin** in heart of **transgenic** mice. Echocardiography analysis indicated that **melusin** over-expression induced a mild cardiac hypertrophy in basal conditions (30% increase in interventricular septum thickness) with no obvious structural and functional alterations. After prolonged pressure overload (12 weeks), **melusin** overexpressing hearts underwent further hypertrophy retaining concentric LV remodeling and full contractile function, whereas wild-type LV showed pronounced chamber dilation with an impaired contractility. Analysis of signaling pathways indicated that **melusin** overexpression induced increased basal phosphorylation of GSK3 $\beta$  and ERK1/2. Moreover, AKT, GSK3 $\beta$  and ERK1/2 were hyper-phosphorylated on pressure overload in **melusin** overexpressing compared with wild-type mice. In addition, after 12 weeks of pressure overload LV of **melusin** overexpressing mice showed a very low level of cardiomyocyte apoptosis and stromal tissue deposition, as well as increased capillary density compared with wild-type. These results demonstrate that **melusin** overexpression allows prolonged concentric compensatory hypertrophy and protects against the transition toward cardiac dilation and failure in response to long-standing pressure overload. .COPYRGT. 2005 American Heart Association, Inc.

CT Medical Descriptors:

\*congestive cardiomyopathy: DI, diagnosis

\*heart left ventricle overload: DI, diagnosis

protein expression

protein determination

heart ventricle remodeling

**transgenic** mouse

echocardiography

heart ventricle septum

heart left ventricle contractility

wild type

signal transduction

enzyme phosphorylation

apoptosis

heart dilatation

heart failure

nonhuman

mouse

rat

animal experiment

animal model

controlled study

animal tissue

animal cell

article

priority journal

Drug Descriptors:

\*binding protein: EC, endogenous compound

**\*melusin**: EC, endogenous compound

betal integrin: EC, endogenous compound

mitogen activated protein kinase 3: EC, endogenous compound

mitogen activated protein kinase 1: EC, endogenous compound

protein kinase B: EC, endogenous compound

glycogen synthase kinase 3alpha: EC, endogenous compound  
unclassified drug

RN (mitogen activated protein kinase 3) 137632-07-6; (mitogen activated  
protein kinase 1) 137632-08-7; (protein kinase B) 148640-14-6

L3 ANSWER 4 OF 4 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on  
STN

AN 2005:563501 SCISEARCH

GA The Genuine Article (R) Number: 930DR

TI Cardiac overexpression of **melusin** protects from dilated  
cardiomyopathy due to long-standing pressure overload

AU De Acetis M; Notte A; Accornero F; Selvetella G; Brancaccio M; Vecchione  
C; Sbroglio M; Collino F; Pacchioni B; Lanfranchi G; Aretini A; Ferretti  
R; Maffei A; Altruda F; Silengo L; Tarone G (Reprint); Lembo G

CS Univ Turin, Dept Genet Biol & Biochem, Via Santena, 5Bis, I-10126 Turin,  
Italy (Reprint); Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin,  
Italy; IRCCS, Dept Angiocardioneurol, Pozzilli, IS, Italy; San Giovanni  
Battista Hosp, Expt Med Res Ctr, Turin, Italy; Univ Roma La Sapienza, Dept  
Expt Med & Pathol, Rome, Italy  
guido.tarone@unito.it; lembo@neuromed.it

CYA Italy

SO CIRCULATION RESEARCH, (27 MAY 2005) Vol. 96, No. 10, pp. 1087-1094.  
ISSN: 0009-7330.

PB LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA 19106-3621  
USA.

DT Article; Journal

LA English

REC Reference Count: 27

ED Entered STN: 9 Jun 2005

Last Updated on STN: 9 Jun 2005

AB We have previously shown that genetic ablation of **melusin**, a  
muscle specific beta 1 integrin interacting protein, accelerates left  
ventricle ( LV) dilation and heart failure in response to pressure  
overload. Here we show that **melusin** expression was increased  
during compensated cardiac hypertrophy in mice subjected to 1 week  
pressure overload, but returned to basal levels in LV that have undergone  
dilation after 12 weeks of pressure overload. To better understand the  
role of **melusin** in cardiac remodeling, we overexpressed  
**melusin** in heart of **transgenic** mice. Echocardiography  
analysis indicated that **melusin** over-expression induced a mild  
cardiac hypertrophy in basal conditions (30% increase in interventricular  
septum thickness) with no obvious structural and functional alterations.  
After prolonged pressure overload (12 weeks), **melusin**  
overexpressing hearts underwent further hypertrophy retaining concentric  
LV remodeling and full contractile function, whereas wild-type LV showed  
pronounced chamber dilation with an impaired contractility. Analysis of  
signaling pathways indicated that **melusin** overexpression induced  
increased basal phosphorylation of GSK3 beta and ERK1/2. Moreover, AKT,  
GSK3 beta and ERK1/2 were hyper-phosphorylated on pressure overload in  
**melusin** overexpressing compared with wild-type mice. In addition,  
after 12 weeks of pressure overload LV of **melusin** overexpressing  
mice showed a very low level of cardiomyocyte apoptosis and stromal tissue  
deposition, as well as increased capillary density compared with  
wild-type. These results demonstrate that **melusin**  
overexpression allows prolonged concentric compensatory hypertrophy and  
protects against the transition toward cardiac dilation and failure in  
response to long-standing pressure overload.

CC CARDIAC & CARDIOVASCULAR SYSTEMS; HEMATOLOGY; PERIPHERAL VASCULAR DISEASE

ST Author Keywords: **melusin**; cardiac hypertrophy; heart failure;  
signal transduction; fibrosis

STP KeyWords Plus (R): HYPERTROPHY IN-VIVO; **TRANSGENIC MICE**; GENE;  
DYSFUNCTION; EXPRESSION; FAILURE; MECHANISMS; INHIBIT; RAT

RE

Referenced Author |Year | VOL |ARN PG| Referenced Work



(RAU)	(RPY)	(RVL)	(RPG)	(RWK)
ANTOS C L	2002	99	907	P NATL ACAD SCI USA
BADORFF C	2002	109	373	J CLIN INVEST
BONCI D	2003	10	630	GENE THER
BRANCACCIO M	1999	274	29282	J BIOL CHEM
BRANCACCIO M	2003	9	68	NAT MED
BRODAL P	1977	232	705	AM J PHYSIOL
BUENO O F	2002	91	776	CIRC RES
BUENO O F	2000	19	6341	EMBO J
CONDORELLI G	1999	99	3071	CIRCULATION
CONDORELLI G	2002	99	12333	P NATL ACAD SCI USA
DATTA S R	1999	13	2905	GENE DEV
DIFREE G M	2003	284	H830	AM J PHYSIOL-HEART C
ESPOSITO G	2002	105	85	CIRCULATION
FREY N	2003	65	45	ANNU REV PHYSIOL
GALLAGHER A M	1998	32	84	HYPERTENSION
GELPI R J	1991	68	555	CIRC RES
GULICK J	1991	266	9180	J BIOL CHEM
HAASE D	2002	4	23	EUR J HEART FAIL
HUNTER J J	1999	341	1276	NEW ENGL J MED
JUHASZOVA M	2004	113	1535	J CLIN INVEST
KADDOURA S	1996	93	2068	CIRCULATION
LEW A M	1999	341	647	BIOCHEM J 3
LIPS D J	2004	109	1938	CIRCULATION
TSCHOPE C	2004	18	828	FASEB J
VECCHIONE C	2002	105	1700	CIRCULATION
WOLSKA B M	1996	271	H1250	AM J PHYSIOL-HEART C
ZILE M R	2002	105	1503	CIRCULATION

=> d his

(FILE 'HOME' ENTERED AT 10:28:35 ON 25 APR 2006)

FILE 'BIOSIS, MEDLINE, EMBASE, SCISEARCH' ENTERED AT 10:29:37 ON 25 APR 2006

L1 75 S MELUSIN  
L2 0 S L1 AND TRASNGENIC  
L3 4 S L1 AND TRANSGENIC

=> s l1 and transgen

=>

=> d his

(FILE 'HOME' ENTERED AT 10:28:35 ON 25 APR 2006)

FILE 'BIOSIS, MEDLINE, EMBASE, SCISEARCH' ENTERED AT 10:29:37 ON 25 APR 2006

L1 75 S MELUSIN  
L2 0 S L1 AND TRASNGENIC  
L3 4 S L1 AND TRANSGENIC